Answers are grounded in this paper and cite their sources.
Background: Over eighty percent of renal cell carcinomas of the clear cell type (ccRCC) constitutively secrete Vascular Endothelial Growth Factor-A (VEGF-A), due to a defect in the von Hippel Lindau (VHL) gene.These tumors are therefore highly angiogenic, making metastasized ccRCC (m-ccRCC) patients the prime candidates for anti-angiogenic therapy.Angiogenesis inhibition nowadays forms the backbone of first-line treatment of m-ccRCC patients.Despite prolongation of disease-free and overall survival, common experience is that resistance develops.Objective: To get more insight in the pathophysiological mechanisms that underlie disease progression under anti-angiogenic therapy. Methods:We extensively analyzed from a 68-year-old male m-ccRCC patient the primary tumor and the corresponding pulmonary metastasis that initially responded well to anti-angiogenic treatment, but ultimately progressed.Results: We show that anti-angiogenic treatment induced a phenotypic adaptation in the lung lesion, characterized by infiltration of tumor cells along and even in the pulmonary vasculature, resembling pulmonary lymphangitis carcinomatosis.This phenotype was radiologically reflected by a cloudy pattern on CT.Conclusions: These observations suggest that pulmonary metastases of renal cell carcinoma can respond to anti-angiogenic therapies by adopting a diffuse phenotype that allows progression in an angiogenesis-independent fashion through co-option.
No takes yet. Share an insight, caveat, or question.
A 2018 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: